Last reviewed · How we verify

NCT06905132

Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma

Recruiting now Phase 2 Last updated 30 March 2026
What this trial tests

Phase 2 trial testing Hypofractionated Radiation Therapy in Soft Tissue Sarcoma in 40 participants. Currently enrolling.

Timeline
1 April 2025
Primary endpoint
27 March 2029
27 March 2030

Quick facts

Lead sponsorMedical University of South Carolina
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 April 2025
Primary completion27 March 2029
Estimated completion27 March 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Medical University of South Carolina

Who can join

18 and older, any sex, with Soft Tissue Sarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research study is to preserve healthy tissue around the cancer on the arm(s) and/or leg(s) using Hypofractionated radiotherapy, while treating the cancer and preventing it from spreading to other areas of the body.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hypofractionated Radiation Therapy

Trials testing the same drug.

Other recruiting trials for Soft Tissue Sarcoma

Currently open trials in the same condition.

Other Medical University of South Carolina trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06905132.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing